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A B S T R A C T
Background
This review is one of a suite of six Cochrane reviews looking at the primary medical management options for patients with chronic
rhinosinusitis.
Chronic rhinosinusitis is a common condition involving inflammation of the lining of the nose and paranasal sinuses. It is characterised
by nasal blockage and nasal discharge, facial pressure/pain and loss of sense of smell. The condition can occur with or without nasal
polyps. Oral corticosteroids are used to control the inflammatory response and improve symptoms.
Objectives
To assess the effects of a short course of oral corticosteroids as an adjunct (’add-on’) therapy in people with chronic rhinosinusitis who
are already on standard treatments.
Search methods
The Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; Central Register of Controlled Trials (CEN-
TRAL 2015, Issue 7); MEDLINE; EMBASE; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials.
The date of the search was 11 August 2015.
Selection criteria
Randomised controlled trials (RCTs) comparing a short course (up to 21 days) of oral corticosteroids to placebo or no treatment, where
all patients were also receiving pharmacological treatment for chronic rhinosinusitis.
Data collection and analysis
We used the standard methodological procedures expected by Cochrane. Our primary outcomes were disease-specific health-related
quality of life (HRQL), patient-reported disease severity, and the adverse event of mood or behavioural disturbances. Secondary
outcomes included general HRQL, endoscopic nasal polyp score, computerised tomography (CT) scan score, and the adverse events
of insomnia, gastrointestinal disturbances and osteoporosis. We used GRADE to assess the quality of the evidence for each outcome;
this is indicated in italics.
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Main results
Two trials with a total of 78 participants met the inclusion criteria. Both the populations and the ’standard’ treatments differed in the
two studies.
Oral steroids as an adjunct to intranasal corticosteroids
One trial in adults with nasal polyps included 30 participants. All participants used intranasal corticosteroids and were randomised to
either short-course oral steroids (oral methylprednisolone, 1 mg/kg and reduced progressively over a 21-day treatment course) or no
additional treatment. None of the primary outcome measures of interest in this review were reported by the study. There may have
been an important reduction in the size of the polyps (measured by the nasal polyps score, a secondary outcome measure) in patients
receiving oral steroids and intranasal corticosteroids, compared to intranasal corticosteroids alone (mean difference (MD) -0.46, 95%
confidence interval (CI) -0.87 to -0.05; 30 participants; scale 1 to 4) at the end of treatment (21 days). This corresponds to a large
effect size, but we are very uncertain about this estimate as we judged the study to be at high risk of bias. Moreover, longer-term data
were not available and the other outcomes of interest were not reported.
Oral steroids as an adjunct to antibiotics
One trial in children (mean age of eight years) without nasal polyps included 48 participants. The trial compared oral corticosteroids
(oral methylprednisolone, 1 mg/kg and reduced progressively over a 15-day treatment course) with placebo in participants who also
received a 30-day course of antibiotics. This study addressed one of the primary outcome measures (disease severity) and one secondary
outcome (CT score). For disease severity the four key symptoms used to define chronic rhinosinusitis in children (nasal blockage,
nasal discharge, facial pressure, cough) were combined into one score. There was a greater improvement in symptom severity 30 days
after the start of treatment in patients who received oral steroids and antibiotics compared with placebo and antibiotics (MD -7.10,
95% CI -9.59 to -4.61; 45 participants; scale 0 to 40). The observed mean difference corresponds to a large effect size. At the same
time point there was a difference in CT scan score (MD -2.90, 95% CI -4.91 to -0.89; 45 participants; scale 0 to 24). We assessed the
quality of the evidence to be low.
There were no data available for the longer term (three months).
Authors’ conclusions
There might be an improvement in symptom severity, polyps size and condition of the sinuses when assessed using CT scans in patients
taking oral corticosteroids when these are used as an adjunct therapy to antibiotics or intranasal corticosteroids, but the quality of the
evidence supporting this is low orvery low (we are uncertain about the effect estimate; the true effect may be substantially different from
the estimate of the effect). It is unclear whether the benefits of oral corticosteroids as an adjunct therapy are sustained beyond the short
follow-up period reported (up to 30 days), as no longer-term data were available.
There were no data in this review about the adverse effects associated with short courses of oral corticosteroids as an adjunct therapy.
More research in this area, particularly research evaluating longer-term outcomes and adverse effects, is required.
P L A I N L A N G U A G E S U M M A R Y
Short-term oral corticosteroids in addition to other treatments for chronic rhinosinusitis
Review question
We reviewed the evidence for the benefits and harms of adding a short course (typically up to 14 days) of corticosteroid given by mouth
to people with chronic rhinosinusitis who were also receiving another type of treatment (such as corticosteroids delivered through the
nose).
Background
Chronic rhinosinusitis is a common condition that is defined as inflammation of the nose and paranasal sinuses (a group of air-filled
spaces behind the nose, eyes and cheeks). Patients with chronic rhinosinusitis experience at least two or more of the following symptoms
for at least 12 weeks: blocked nose, discharge from their nose or runny nose, pain or pressure in their face and/or a reduced sense of
smell (hyposmia). Some people will also have nasal polyps, which are grape-like swellings of the normal nasal lining inside the nasal
passage and sinuses.
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Short courses of oral corticosteroids are a widely used treatment for chronic rhinosinusitis. They work by controlling inflammation
and when polyps are present they rapidly reduce the size of the polyps to improve symptoms. The adverse effects of corticosteroids can
include insomnia, mood changes and gastrointestinal changes (such as stomach pain, heartburn, diarrhoea, constipation, nausea and
vomiting). When given over the longer term, or through many repeated short courses, it is also possible to develop osteoporosis (fragile
bones).
Study characteristics
This review includes evidence up to 11 August 2015. We included two randomised controlled trials with a total of 78 participants.
One trial involved 30 adults with nasal polyps. Participants received either intranasal corticosteroids and oral corticosteroids or only
intranasal corticosteroids. The only result reported of interest to this review was whether the size of the nasal polyps was reduced, when
these treatments were completed (three weeks).
One trial involved 48 children (mean age of eight years) with chronic rhinosinusitis but no nasal polyps. Participants received either
antibiotics and oral corticosteroids or only antibiotics and a placebo (sugar pill). The oral corticosteroids and placebo were given for
15 days and the antibiotics were given for 30 days. The trial reported findings when the antibiotic treatment was completed (at one
month).
Key results
At the end of a three-week treatment course, people who took both intranasal corticosteroids and oral steroids may have had smaller
nasal polyps than people who just received intranasal corticosteroids. The trial did not follow up people to determine whether the
polyp size increased after the end of the trial. The trial did not provide information on adverse events or other outcomes important to
patients, such as symptom severity or quality of life.
Children who received both antibiotics and oral corticosteroids seemed to have a lower total symptom score and better computerised
tomography (CT) scan score after treatment compared with children who received antibiotics and control treatment. The reporting of
adverse effects in this trial was not very clear and so is difficult to tell if any participant experienced gastrointestinal disturbances, mood
changes or difficulty in sleeping.
Quality of the evidence
We judged the quality of the evidence for oral steroids plus intranasal steroids for adults with nasal polyps to be very low (we are very
uncertain about the estimate) as the evidence comes from one trial that has a low number of participants. The trial had a high risk of
bias due to the way it was conducted. The trial did not report adverse events and did not report results after the end of treatment.
We judged the quality of the evidence for oral steroids plus antibiotics for children to be low (further research is very likely to have an
important impact on our confidence in the effect estimate and is likely to change the estimate) as the evidence comes from one small
trial. The trial did not have a high risk of bias, but it only included children without nasal polyps, who might not have the same results
as adults with nasal polyps. The trial did not report results after the end of treatment and the adverse effects of treatment were not well
reported.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Short-course oral corticosteroids compared to no oral corticosteroid treatment (intranasal steroids in both arms) for chronic rhinosinusitis
Patient or population: chronic rhinosinusit is
Setting: ENT departments
Intervention: short-course oral steroids and intranasal steroids
Comparison: intranasal steroids alone (no oral steroid treatment)
Outcomes
No. of part icipants
(studies)
Relative effect (95%CI) Anticipated absolute effects∗ (95% CI) Quality What happens
Without oral steroids With oral steroids Difference
Disease-specif ic
health-related quality of
lif e
- No RCT reported this outcome
Disease severity - pa-
t ient-reported symptom
score
- No RCT reported this outcome
Adverse ef fect: mood
or behavioural distur-
bances
- No RCT reported this outcome
Health-related quality
of lif e
- No RCT reported this outcome
Adverse ef fect: insom-
nia
- No RCT reported this outcome
Adverse
ef fect: gastrointest inal
disturbances - not mea-
sured
- No RCT reported this outcome
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval;RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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B A C K G R O U N D
Description of the condition
Chronic rhinosinusitis is defined as inflammation of the nose and
paranasal sinuses characterised by two or more symptoms, one of
whichmust be nasal blockage/obstruction/congestion or nasal dis-
charge (anterior/posterior nasal drip). The other possible symp-
toms include facial pain/pressure, reduction or loss of sense of
smell (in adults) or cough (in children). Symptomsmust have con-
tinued for at least 12 weeks. In addition, people must have either
mucosal changes within the ostiomeatal complex and/or sinuses as
evidenced by a computerised tomography (CT) scan and/or endo-
scopic signs of at least one of the following: nasal polyps, mucop-
urulent discharge primarily from middle meatus or oedema/mu-
cosal obstruction primarily in the middle meatus (EPOS 2012).
Chronic rhinosinusitis represents a common source of ill health;
11% of UK adults reported chronic rhinosinusitis symptoms in a
worldwide population study (Hastan 2011). Symptoms, including
nasal obstruction, nasal discharge, facial pain, anosmia and sleep
disturbance, have a major impact on quality of life, reportedly
greater in several domains of the SF-36 than angina or chronic res-
piratory disease (Gliklich 1995). Acute exacerbations, inadequate
symptom control and respiratory disease exacerbation are com-
mon. Complications are rare, but may include visual impairment
and intracranial infection.
Two major phenotypes of chronic rhinosinusitis have been iden-
tified based on the presence or absence of nasal polyps on ex-
amination. Nasal polyps are tumour-like hyperplastic swellings of
the nasal mucosa, most commonly originating from within the
ostiomeatal complex (Larsen 2004). Chronic rhinosinusitis with
nasal polyps (CRSwNP) is diagnosed when polyps are seen (on
direct or endoscopic examination) bilaterally in the middle mea-
tus. The acronym CRSsNP is used for the condition in which no
polyps are present.
Although the aetiology of chronic rhinosinusitis is not fully un-
derstood, it may involve abnormalities in the host response to ir-
ritants, commensal and pathogenic organisms and allergens, ob-
struction of sinus drainage pathways, abnormalities of normal mu-
cociliary function, loss of the normal mucosal barrier or infection.
Two typical profilesmay be observed with respect to inflammatory
mediators; in eosinophilic chronic rhinosinusitis, which is typi-
cally associated with nasal polyps, high levels of eosinophils, im-
munoglobulin E (IgE) and interleukin (IL)-5 may be found, while
in neutrophilic chronic rhinosinusitis, more often associated with
chronic rhinosinusitis without polyps, neutrophils predominate,
with elevated interferon (IFN) gamma, IL-8 and tumour necrosis
factor (TNF) (EPOS 2012).
While treatment decisions should be made based on an under-
standing of the patient’s chronic rhinosinusitis phenotype and
likely aetiology, in practice treatment may be initiated without
knowledge of the polyp status, particularly in primary care. This
review (and most of its companion reviews) consider patients with
and without polyps together in the initial evaluation of treatment
effects. However, subgroup analyses explore potential differences
between them.
The most commonly used interventions for chronic rhinosinusitis
are used either topically (sprayed into the nose) or systemically (by
mouth) and include steroids, antibiotics and saline.
Description of the intervention
Short courses of oral steroids are widely used in medicine for a
variety of inflammatory conditions. In patients with chronic rhi-
nosinusitis they are often used with a view to gaining a rapid im-
provement in symptoms and to allow improved access for topically
applied agents. They are often given over a seven- to 21-day period
and may be at a fixed dose or a reducing dose over the course. This
strategy is thought to reduce the risk of adverse effects (Mygind
1996). A wide spectrum of adverse events are reported with sys-
temic steroid usage (see Table 1); however, data on the incidence
in association with chronic rhinosinusitis are lacking. While it is
possible to extrapolate findings from trials in other diseases, there
is a risk that the incidence is disease-specific; for example, a high
incidence of avascular necrosis is seen with high-dose steroid use
in systemic lupus erythematosus, which is in part attributed to
the underlying disease process and severity as well as the higher
dosages prescribed in severe disease (Da Silva 2006).
Adverse effects associated with short-term oral steroid use are
said to include gastrointestinal disturbances, insomnia and altered
mental states. However, there are few or no published data on the
frequency of these effects when short-term courses are prescribed.
Adverse effects associated with long-term use of oral steroids are
also listed in Table 1.
How the intervention might work
Short courses of oral steroids are most often used in patients with
chronic rhinosinusitis and nasal polyps. The intention is to reduce
the inflammation in order to produce a rapid reduction in the
size of the polyps, to improve symptoms and allow better penetra-
tion of topical treatments into the nasal cavity. They may be used
in a similar way for patients with chronic rhinosinusitis without
polyps, who have severe nasal obstruction or complete anosmia
(loss of sense of smell). The initial effect of treatment is expected
to be immediate. Any observed improvement may continue, es-
pecially if one effect of the intervention is to improve the bio-
availability of an adjunct treatment.
There is, however, a lack of evidence regarding the optimal treat-
ment regimen of oral steroids with respect to indication, dose and
duration. The optimum usage of steroids is clinically important as
it may reduce the need for surgery by providing good symptomatic
control.
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Why it is important to do this review
Short courses of oral steroids are widely used as a form of add-on
therapy in patients with chronic rhinosinusitis. This review and a
closely related new review of ’Short-course oral steroids alone for
chronic rhinosinusitis’, Head 2016a, update and expand a previ-
ous Cochrane review that looked at this treatment in patients with
nasal polyps (Martinez-Devesa 2011). This review seeks to estab-
lish the additional benefits (and harms) of steroids, when added
on to existing therapies for chronic rhinosinusitis. In contrast, the
companion review will seek to establish the relative effectiveness
(and harms) of oral steroids when compared to no treatment or
other commonly used agents for chronic rhinosinusitis (such as
intranasal corticosteroids).
This review is one of a suite of Cochrane reviews looking at com-
mon management options for patients with chronic rhinosinusi-
tis (Chong 2016a; Chong 2016b; Chong 2016c; Head 2016a;
Head 2016b), and we use the same outcome measures across the
reviews. We did not include studies designed to evaluate interven-
tions in the immediate peri-surgical period, which are focused on
attempting to assess the impact of the intervention on the surgical
procedure or to modify the post-surgical results.
O B J E C T I V E S
To assess the effects of a short course of oral corticosteroids as an
adjunct (’add-on’) therapy in people with chronic rhinosinusitis
who are already on standard treatments.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies with the following design characteristics:
• randomised controlled trials, including cluster-randomised
trials and quasi-randomised trials (cross-over trials were only to
be included if the data from the first phase were available); and
• patients were followed up for at least two weeks.
We excluded studies with the following design characteristics:
• randomised patients by side of nose (within-patient
controlled) because it is difficult to ensure that the effects of any
of the interventions considered can be localised; or
• perioperative studies, where the sole purpose of the study
was to investigate the effect of the intervention on surgical
outcome.
Types of participants
Patients with chronic rhinosinusitis, whether with polyps or with-
out polyps.
We excluded studies that included a majority of patients with:
• cystic fibrosis;
• allergic fungal sinusitis/eosinophilic fungal/mucinous
rhinosinusitis;
• aspirin-exacerbated respiratory disease;
• antrochoanal polyps (benign polyps originating from the
mucosa of the maxillary sinus);
• malignant polyps;
• primary ciliary dyskinesia;
• gross immunodeficiency (congenital or acquired);
• a history of surgery for nasal polyps within six weeks of
entry to the study.
Types of interventions
We included all short (see below) courses of oral steroids, regardless
of dose. This includes:
• prednisone;
• prednisolone;
• methylprednisolone;
• hydrocortisone;
• cortisone acetate.
Short courses of oral steroids are defined as lasting up to, but not
exceeding, 21 days.
The main comparators were:
• oral steroids plus intranasal corticosteroids versus placebo or
no treatment plus intranasal corticosteroids.
Other possible comparison pairs included:
• oral steroid plus co-intervention X versus placebo/no
treatment plus co-intervention X (’co-intervention X’ refers to
any of the other possible co-interventions).
This review is part of a larger series of six reviews for the treatment
of chronic rhinosinusitis:
• Intranasal steroids versus placebo or no intervention for
chronic rhinosinusitis (Chong 2016b).
• Different types of intranasal steroids for chronic
rhinosinusitis (Chong 2016a). This review compares different
classes, doses and delivery methods of intranasal corticosteroids
for chronic rhinosinusitis.
• Short-course oral steroids alone for chronic rhinosinusitis
(Head 2016a). This review compares short-course oral steroids
alone with placebo or no intervention, or against other
pharmacological interventions such as antibiotics or nasal saline
irrigation.
• Short-course oral steroids as an adjunct therapy for chronic
rhinosinusitis (this review). This review compares oral steroids
where they have been used as add-on therapy to other treatments
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for chronic rhinosinusitis (such as intranasal corticosteroids,
antibiotics or saline solution).
• Saline irrigation for chronic rhinosinusitis (Chong 2016c).
This review compares nasal saline irrigation for chronic
rhinosinusitis with both placebo/no intervention and with
intranasal corticosteroids or antibiotics.
• Systemic and topical antibiotics for chronic rhinosinusitis
(Head 2016b). This review compares both topical and systemic
antibiotics with placebo/no treatment, two different antibiotics
with each other and antibiotics with intranasal corticosteroids.
Types of outcome measures
We analysed the following outcomes in the review, but we did not
use them as a basis for including or excluding studies.
Both short-term (at the end of treatment) and long-term effects
are important, therefore we evaluated outcomes at the end of treat-
ment or within three weeks thereof in addition to three to six
months, six to 12 months and more than 12 months. For adverse
events, we analysed data from the longest time periods.
Primary outcomes
• Health-related quality of life, using disease-specific health-
related quality of life scores, such as the Sino-Nasal Outcome
Test-22 (SNOT-22), Rhinosinusitis Outcome Measures-31
(RSOM-31) and SNOT-20.
• Disease severity, as measured by patient-reported symptom
score (such as the Chronic Sinusitis Survey (CSS) questionnaire
and visual analogue scales). In the absence of validated symptom
score data, patient-reported individual symptom scores were
reported for the following symptoms: nasal obstruction/
blockage/congestion, nasal discharge (rhinorrhoea), facial
pressure/pain, loss of sense of smell (adults), cough (children).
• Significant adverse effect: mood or behavioural
disturbances.
Secondary outcomes
• Health-related quality of life, using generic quality of life
scores, such as the SF-36, EQ-5D and other well-validated
instruments.
• Other adverse effects: gastrointestinal disturbances.
• Other adverse effects: insomnia.
• Other adverse effects: osteoporosis (where follow-up was at
least six months).
• Endoscopic score (depending on population, either nasal
polyps size score or endoscopy score, e.g. Lund-Mackay/Lund-
Kennedy).
• Computerised tomography (CT) scan score (e.g. Lund-
Mackay).
The adverse events that we aimed to collect from studies including
one of the various comparators listed above were the same as those
adverse events identified in the methods section of the compan-
ion reviews assessing the effects of those interventions as primary
treatments. For example, for studies in which all participants re-
ceived intranasal corticosteroids, the list of adverse events will also
include those specifically for intranasal corticosteroids as found in
Chong 2016a and Chong 2016b.
Search methods for identification of studies
The Cochrane ENT Information Specialist conducted systematic
searches for randomised controlled trials and controlled clinical
trials. There were no language, publication year or publication
status restrictions. The date of the search was 11 August 2015.
Electronic searches
The Information Specialist searched:
• the Cochrane Register of Studies ENT Trials Register
(searched 11 August 2015);
• the Cochrane Central Register of Controlled Trials
(CENTRAL 2015, Issue 7);
• Ovid MEDLINE (1946 to July week 5 2015);
◦ Ovid MEDLINE (In-Process & Other Non-Indexed
Citations) (searched 11 August 2015);
◦ PubMed (as a top up to searches in Ovid MEDLINE)
(searched 11 August 2015);
• Ovid EMBASE (1974 to 2015 week 32);
• ClinicalTrials.gov, www.clinicaltrials.gov (search via the
Cochrane Register of Studies) (searched 11 August 2015);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (searched 11 August 2015);
• Google Scholar (searched 11 August 2015).
The Information Specialist modelled subject strategies for
databases on the search strategy designed for CENTRAL. Where
appropriate, theywere combined with subject strategy adaptations
of the highly sensitive search strategy designed by Cochrane for
identifying randomised controlled trials and controlled clinical tri-
als (as described in theCochraneHandbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011). Search
strategies for major databases including CENTRAL are provided
in Appendix 1.
Searching other resources
We scanned the reference lists of identified publications for addi-
tional trials and contacted trial authors where necessary. In addi-
tion, the Information Specialist searched PubMed, The Cochrane
Library and Google to retrieve existing systematic reviews relevant
to this systematic review, so that we could scan their reference lists
for additional trials.
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Data collection and analysis
Selection of studies
Two review authors independently screened all titles and abstracts
of the studies obtained from the database searches to identify po-
tentially relevant studies. The same two review authors evaluated
the full text of each potentially relevant study to determine if it
met the inclusion and exclusion criteria for this review.
We resolved differences by discussion and consensus, with the in-
volvement of a third author for clinical and/methodological input
where necessary.
Data extraction and management
Two review authors independently extracted data from each study
using a standardised data collection form (see Appendix 2). If we
had found a study that had more than one publication, we would
have aimed to retrieve all publications to ensure complete extrac-
tion of data. Where there were discrepancies in the data extracted
by different review authors, we checked these against the original
reports and resolved differences by discussion and consensus, with
the involvement of a third author or a methodologist where ap-
propriate. We would have contacted the original study authors for
clarification or for missing data whenever needed. If differences
had have been found between publications of a study, we would
have contacted the original authors for clarification. We would
have used data from the main paper(s) if no further information
was found.
We included key characteristics of the studies, such as study design,
setting, sample size, population and how outcomes were defined
or collected in the studies. In addition, we also collected baseline
information on prognostic factors or effect modifiers. For this
review, these included:
• presence or absence of nasal polyps;
• baseline nasal polyp score (where appropriate);
• whether the patient has had previous sinus surgery;
• number of previous courses of oral steroids.
For the outcomes of interest to the review, we extracted the find-
ings of the studies on an available case analysis basis; i.e. we in-
cluded data from all patients available at the time points based on
the treatment randomised whenever possible, irrespective of com-
pliance or whether patients had received the treatment as planned.
In addition to extracting pre-specified information about study
characteristics and aspects of methodology relevant to risk of bias,
we extracted the following summary statistics for each trial and
each outcome:
• For continuous data: the mean values, standard deviations
and number of patients for each treatment group. Where
endpoint data were not available, we extracted the values for
change from baseline. We analysed data from measurement
scales such as SNOT-22 and EQ-5D as continuous data.
• For binary data: the numbers of participants experiencing
an event and the number of patients assessed at the time point.
• For ordinal scale data: if the data appeared to be
approximately normally distributed or if the analysis that the
investigators performed suggested parametric tests were
appropriate, then we treated the outcome measures as
continuous data. Alternatively, if data were available, we
converted into binary data.
We prespecified the time points of interest for the outcomes in this
review. While studies may report data at multiple time points, we
only extracted the longest available data within the time points of
interest. For example, for ’medium-term’ follow-up periods, our
time point is defined as ’three to six months’ post-randomisation.
If a study reported data at three, four and six months, we only
extracted and analysed the data for the six-month follow-up.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of each
included study. We followed the guidance in the Cochrane Hand-
book for Systematic Reviews of Interventions (Handbook 2011), and
we used theCochrane ’Risk of bias’ tool.With this tool we assessed
the risk of bias as ’low’, ’high’ or ’unclear’ for each of the following
six domains:
• sequence generation;
• allocation concealment;
• blinding of participants, personnel and outcome assessment;
• incomplete outcome data;
• selective reporting;
• other sources of bias.
Measures of treatment effect
If dichotomous outcomes were found, we would have summarised
the effects (e.g. proportion of patients with symptom resolution) as
risk ratios (RR) with CIs. For the key outcomes that we presented
in the ’Summary of findings’ table, we would have also expressed
the results as absolute numbers and compared to the assumed risk.
The assumed baseline risk is typically either (a) the median of the
risks of the control groups in the included studies, this being used
to represent a ’medium-risk population’ or, alternatively, (b) the
average risk of the control groups in the included studies is used
as the ’study population’ (Handbook 2011).
For continuous outcomes, we expressed treatment effects as amean
difference (MD) with standard deviation (SD) or as standardised
mean difference (SMD) if different scales have been used to mea-
sure the same outcome. We provided a clinical interpretation of
the SMD values.
Unit of analysis issues
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This review did not use data from phase II of cross-over studies or
from studies where the patient was not the unit of randomisation,
i.e. studies where the side (right versus left) was randomised.
If we had found cluster-randomised trials, we would have analysed
these according to the methods in section 16.3.3 of the Cochrane
Handbook for Systematic Reviews of Interventions (Handbook
2011).
Dealing with missing data
We would have tried to contact study authors via email when-
ever the outcome of interest was not reported, if the methods of
the study had suggested that the outcome had been measured,
or where data presented in the paper were in graphical format,
in order to try to obtain the study values for the study results.
We would have done the same if not all data required for meta-
analysis were reported, unless the missing data were standard de-
viations. If standard deviation data were not available, we would
have approximated these using the standard estimation methods
from P values, standard errors or 95% CIs if these were reported as
detailed in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Handbook 2011). If it was impossible to estimate these,
we would have contacted the study authors. Apart from imputa-
tions for missing standard deviations, no other imputations were
planned. However, we had to carry out calculations relating to dis-
ease severity (reported as symptom scores) as most of the data were
not measured using validated instruments nor reported in a way
that was comparable across studies (see ’Imputing total symptom
scores’ below).
We extracted and analysed all data using the available case analysis
method.
Imputing total symptom scores
Where a paper did not present information for the total dis-
ease severity in terms of patient-reported symptom scores but did
present data for the results of individual symptoms, we used the
symptoms covering the important domains of the EPOS chronic
rhinosinusitis diagnosis criteria, EPOS 2012, to calculate a total
symptom score. The EPOS 2012 criteria for chronic rhinosinusitis
require at least two symptoms. One of the symptoms must be ei-
ther nasal blockage or nasal discharge; other symptoms can include
facial pressure/pain, loss of sense of smell (for adults) or cough (for
children). Where mean final values or changes from baseline were
presented in the paper for the individual symptoms we summed
these to calculate a ’total symptom score’. We calculated standard
deviations for the total symptom score as if the symptoms were in-
dependent, random variables that were normally distributed. We
acknowledge that there is likely to be a degree of correlation be-
tween the individual symptoms, however we used this process be-
cause the magnitude of correlation between the individual symp-
toms is not currently well understood (no evidence found). If the
correlation is high, the summation of variables as discrete vari-
ables is likely to give a conservative estimate of the total variance
of the summed final score. If the correlation is low, this method
of calculation will underestimate the standard deviation of the to-
tal score. However, the average patient-reported symptom scores
have a correlation coefficient of about 0.5; if this is also applica-
ble to chronic rhinosinusitis symptoms, the method used should
have minimal impact (Balk 2012). As this method of calculation
does not take into account weighting of different symptoms (no
evidence found), we downgraded all the disease severity outcomes
for lack of use of validated scales whenever this occurred.
Assessment of heterogeneity
If we had found more than one study for each of the compar-
isons, we would have assessed clinical heterogeneity (which may
be present even in the absence of statistical heterogeneity) by ex-
amining the included trials for potential differences between stud-
ies in the types of participants recruited, interventions or controls
used and the outcomes measured.
If heterogeneity had been detected we would have assessed it by
visually inspecting the forest plots and by considering the Chi² test
(with a significance level set at P value < 0.10) and the I² statistic,
which calculates the percentage of variability that is due to het-
erogeneity rather than chance, with I² values over 50% suggesting
substantial heterogeneity (Handbook 2011).
Assessment of reporting biases
We assessed reporting bias as between-study publication bias and
within-study outcome reporting bias.
Outcome reporting bias (within-study reporting bias)
We assessed within-study reporting bias by comparing the out-
comes reported in the published report against the study proto-
col, whenever this could be obtained. When the protocol was not
available, we compared the outcomes reported to those listed in
the methods section. If results were mentioned but not reported
adequately in a way that allowed analysis (e.g. the report onlymen-
tioned whether the results were statistically significant or not), bias
is likely to occur in a meta-analysis. We sought further informa-
tion from the study authors. If no further information could be
obtained, we noted this as being a ’high’ risk of bias. Quite often
there was insufficient information to judge the risk of bias; we
noted this as an ’unclear’ risk of bias (Handbook 2011).
Publication bias (between-study reporting bias)
We would have assessed funnel plots if sufficient trials (more than
10) were available for an outcome. If asymmetry of the funnel plot
was observed, wewould have conductedmore formal investigation
using the methods proposed by Egger 1997.
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Data synthesis
If we had found more than one study in within a comparison pair,
we would have conducted all meta-analyses using Review Man-
ager 5.3 (RevMan 2014). If we had found dichotomous data, we
would have analysed treatment differences as a risk ratio (RR) cal-
culated using theMantel-Haenszel methods.We would have anal-
ysed time-to-event data using the generic inverse variance method.
For continuous outcomes, if we had found that data were from the
same scale, we might have pooled mean values obtained at follow-
up with change outcomes and reported this as a MD. However, if
the SMD had to be used as an effect measure, we would not have
pooled change and endpoint data.
When statistical heterogeneity is low, random-effects versus fixed-
effect methods yield trivial differences in treatment effects. How-
ever, when statistical heterogeneity is high, the random-effects
method provides a more conservative estimate of the difference.
Subgroup analysis and investigation of heterogeneity
Had we found more than one study for each comparison pair, we
would have conducted the following subgroup analyses regard-
less of whether statistical heterogeneity was observed, as these are
widely suspected to be potential effect modifiers:
• whether patients had chronic rhinosinusitis without nasal
polyps, chronic rhinosinusitis with nasal polyps, were a mixed
group or the status of polyps is not known or not reported.
We would have undertaken the subgroup analysis as although
there appears to be a considerable overlap between the two
forms of chronic rhinosinusitis with regards to inflammatory pro-
file, clinical presentation and effect of treatment (Cho 2012;
DeMarcantonio 2011; Ebbens 2010; Fokkens 2007; Ragab 2004;
Ragab 2010; van Drunen 2009), there is some evidence point-
ing to differences in the respective inflammatory profiles (Kern
2008; Keswani 2012; Tan 2011; Tomassen 2011; Zhang 2008;
Zhang 2009), and potentially even differences in treatment out-
come (Ebbens 2011).
We would have presented the main analyses of this review accord-
ing to the subgroups of phenotypes of chronic rhinosinusitis. We
would have presented all other subgroup analysis results in tables.
None of the studies had a mixed group of patients. If a mixed
group of patients had been found within the paper, we would have
analysed the study as one of the subgroups (rather than as a mixed
group) if more than 80% of patients had belonged to one category.
In addition to the subgroups above, we had planned to conduct
the following subgroup analyses in the presence of statistical het-
erogeneity:
• patient age (children versus adults);
• dose;
• duration of treatment.
Sensitivity analysis
Had we found more than one study for each comparison, we
would have carried out sensitivity analyses to determine whether
the findings are robust to the decisions made in the course of
identifying, screening and analysing the trials. We had planned
to conduct sensitivity analysis for the following factors, whenever
possible:
• impact of model chosen: fixed-effect versus random-effects
model;
• risk of bias of included studies: excluding studies with high
risk of bias (we define these as studies that have a high risk of
allocation concealment bias and a high risk of attrition bias
(overall loss to follow-up of 20%, differential follow-up
observed);
• how outcomes were measured: we would have investigated
the impact of including data where the validity of the
measurement is unclear.
If any of these investigations had found a difference in the size of
the effect or heterogeneity, we would have mentioned this in the
Effects of interventions section.
GRADE and ’Summary of findings’ table
We used the GRADE approach to rate the overall quality
of evidence for each outcome using the GDT tool (http://
www.guidelinedevelopment.org/) for the main comparison pairs
listed in the Types of interventions section. The quality of evi-
dence reflects the extent to which we are confident that an esti-
mate of effect is correct and we applied this in the interpretation
of results. There are four possible ratings: ’high’, ’moderate’, ’low’
and ’very low’. A rating of ’high’ quality evidence implies that we
are confident in our estimate of effect and that further research is
very unlikely to change our confidence in the estimate of effect.
A rating of ’very low’ quality implies that any estimate of effect
obtained is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision;
• publication bias.
The ’Summary of findings’ table presents only the six top prior-
ity outcomes (disease-specific health-related quality of life, disease
severity score, generic quality of life and three adverse effects:mood
disturbances, gastrointestinal disturbance and insomnia). We did
not include the outcomes of endoscopic score, CT scan score or
the adverse effect osteoporosis in the ’Summary of findings’ table.
Similarly we did not present the results for the individual symp-
toms in the ’Summary of findings’ table.
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R E S U L T S
Description of studies
Results of the search
The searches retrieved a total of 2470 references. We screened the
titles and abstracts and subsequently removed 2424 studies. We
assessed 46 full texts for eligibility and excluded 43 studies. We
included two studies and identified one ongoing study. No studies
are awaiting assessment.
A flow chart of study retrieval and selection is provided in Figure
1.
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Figure 1. Process for sifting search results and selecting studies for inclusion.
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Included studies
Two studies are included in the review (Bülbül 2013; Ozturk
2011). See Characteristics of included studies.
Design
Bülbül 2013 is an unblinded, parallel-group, quasi-randomised
controlled trial (randomised by order of presentation). Ozturk
2011 is a double-blind, parallel-group, randomised, placebo-con-
trolled trial.
Setting
Both studies were conducted in Turkey. Bülbül 2013 was a single-
site study conducted in a university hospital outpatient ear, nose
and throat department, whereas Ozturk 2011 was conducted in
the paediatric ear, nose and throat outpatients clinics of two uni-
versity hospitals.
Participants and sample size
In Bülbül 2013, the two study arms that met the inclusion criteria
for this review consisted of 30 adults (mean age 34.73±16.72)with
a diagnosis of bilateral nasal polyps on endoscopic examination.
Ozturk 2011 included 48 children with a mean age in the oral
steroids group of 8.5 ± 2.9 years and a mean age in the placebo
group of 8.0 ± 2.3 years. All patients had chronic rhinosinusitis
without nasal polyps. The diagnosis of chronic rhinosinusitis was
based of sinonasal symptoms and signs present for a period ofmore
than three months in the presence of abnormalities on coronal
sinus CT scans.
Interventions
Bülbül 2013 compared intranasal steroids alone (budesonide), oral
steroids alone (methylprednisolone) and treatment with both in-
tranasal steroids and oral steroids. No placebo was used. The treat-
ment time was 21 days for all arms. For this review, the only
comparison of interest was the group receiving oral steroids and
intranasal steroids compared with the group receiving intranasal
steroid alone (i.e. oral steroids compared with no treatment, with
both groups receiving concurrent treatment with an intranasal
steroid).
InOzturk 2011, methylprednisolone was prescribed for 15 days at
a dose adjusted to the weight of the child (1 mg/kg/day, maximum
of 40 mg for 10 days) and reduced over the treatment time. Pa-
tients in the control arm received identical-looking lactose tablets
as placebo. In addition, children in both arms of the study re-
ceived broad-spectrum antibiotics (oral amoxicillin/clavulanate at
45/6.3 mg/kg/day, maximum of 2000/285 mg/day) for 30 days
as concurrent treatment.
Outcomes
Bülbül 2013 aimed to investigate the effects of glucocorticoids on
chronic rhinosinusitis with nasal polyps with detection of inflam-
matory response by measurement of nitric oxide levels in nasal
polyp tissue. The only outcome of interest to this review was the
secondary outcome of endoscopic nasal polyp scoremeasured with
Rasp criteria. No information about this scale was presented in the
paper but Coˆ té 2011 indicates that it is a four-point scale, graded
from 1 to 4 (1 = least severe, 4 = most severe). The outcomes were
reported at 21 days, at the end of the treatment course. The study
did not mention whether they measured any adverse events.
Ozturk2011 presents the primary outcome of total symptom score
(comprising a cumulative score for the individual symptoms of
purulent nasal discharge, nasal obstruction, postnasal drainage,
halitosis, cough and facial pain/headache measured using a visual
analogue scale (VAS) of 0 to 10 (0 = none, 10 = most severe, non-
validated) and a CT scan score measured with the Lund-Mackay
scoring system (0 to 24; 0 = least severe, 24 = most severe). The
study also specified that “tolerability was evaluated by means of
medical history, physical examination, and measurement of ad-
verse events. Hypertension, edema, weight gain, increase in ap-
petite, gastrointestinal disturbances, nervousness, agitation, psy-
chosis, headache, mood swings, delirium, euphoria, moon face,
skin atrophy, bruising, hyperpigmentation,muscle weakness, joint
pain, and allergic reactions were defined as clinically significant
adverse events”.
Excluded studies
We excluded 43 papers after reviewing the full paper. Fur-
ther details for the reasons for exclusion can be found in the
Characteristics of excluded studies table. We identified 19 of
these from the excluded papers list in the previous version of
the Cochrane review (Martinez-Devesa 2011). The reasons for
exclusion from the previous review were found to be still valid
under the updated inclusion criteria developed for this review
(Alobid 2005; Blomqvist 2001; Blomqvist 2009; Bonfils 1998;
Bonfils 2003; Bonfils 2006; Chi Chan 1996; Damm 1999;
Hessler 2007; Jankowski 2003a; Jankowski 2003b; Kroflic 2006;
Lildholdt 1988; Lildholdt 1989; Nores 2003; Ragab 2006; Rasp
2000; Sieskiewicz 2006; Stevens 2001).
Thirteen papers were reporting RCTs comparing oral steroid
treatment with placebo or no treatment, but study participants
did not receive any other concurrent treatment (Alobid 2006;
Alobid 2012; Alobid 2014; Benitez 2006; Ecevit 2015; Hissaria
14Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2006; Kapucu 2012; Kirtsreesakul 2011; Kirtsreesakul 2012;
Martinez-Anton 2008; Vaidyanathan 2011; Van Zele 2008; Van
Zele 2010). These studies are included in the Cochrane review of
oral steroids alone for chronic rhinosinusitis (Head 2016a). We
found three protocols for ongoing RCTs: none of these studies
appeared to use oral steroids as an adjunct to other treatment (Chi
2011; NCT00841802; NCT02367118).
Of the remaining eight papers, one included a population of peo-
ple with allergic fungal rhinosinusitis (Rupa 2010), one compared
oral steroids with intranasal steroids, but participants did not re-
ceive any background treatments (Reychler 2015), and six were
either non-randomised studies or commentaries on existing RCTs
(Grammer 2013; Rasp 1997; Remer 2005; Sousa 2009; Tuncer
2003; van Camp 1994).
Ongoing studies
One ongoing study is being conducted to investigate the efficacy
of oral steroids (prednisone 40 mg in reducing doses for 20 days)
followed by intranasal steroids (mometasone), compared with in-
tranasal steroids alone (mometasone) in adults with chronic rhi-
nosinusitis without nasal polyps (NCT01676415). Both groups
also had a concurrent course of antibiotics lasting for three weeks.
The study is due to report results during 2016. See Characteristics
of ongoing studies.
Risk of bias in included studies
For details of the risk of bias in the included studies see the ’Risk
of bias’ tables (Characteristics of included studies). Details of the
risk of bias for each study can be found in Figure 2. A ’Risk of bias’
graph shows our judgements about each risk of bias item presented
as percentages across all included studies (Figure 3).
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
16Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Sequence generation
Both the included studies were randomised and controlled. We
assessed Bülbül 2013 as high risk of bias for sequence generation
as it was quasi-randomised, with the allocation to the arm of the
trial being completed based on the order of presentation. Ozturk
2011 used a random allocation chart based on a table of random
numbers to generate the sequence.
Allocation concealment
We assessed Bülbül 2013 as high risk of bias for allocation con-
cealment as the allocation to the arm of the study was completed
by order of presentation, which allows the people allocating par-
ticipants to treatment group to know exactly which arm partici-
pants are being allocated to. We assessed Ozturk 2011 as having
a low risk of bias for allocation concealment as sealed envelopes
were used to prevent the healthcare personnel from influencing
allocation of participants in the study.
Blinding
As Bülbül 2013 lacked a placebo arm, we assessed that there was a
high risk of bias for blinding of participants and personnel. In ad-
dition, it did not report whether outcome assessment was blinded;
we therefore assessed this to be an unclear risk.We assessedOzturk
2011 to be of unclear risk of bias for blinding of participants and
personnel. Although themethods for blinding were well explained
in the paper and efforts were made to keep the size and appear-
ance of the placebo the same as the active treatment, there was no
discussion on the taste of the tablets. Methylprednisolone has a
distinctive, bitter taste that is different to the slightly sweet taste of
lactose. This may have allowed the blinding to be compromised
and it is noted that one patient did drop out of the study due to the
unpalatability of the active tablet. The method for standardising
reporting by outcome assessors for CT scans was mentioned in
the paper but the risk was unclear for the other outcomes, since
these are mostly patient/parent-reported and the effectiveness of
blinding using the placebo was unclear.
Incomplete outcome data
We assessed both studies to have a low risk of bias for incomplete
outcome data. Bülbül 2013 reported that there were no patients
who dropped out of the study whereas Ozturk 2011 reported a
low rate of participant drop-out (3 out of 48 (6%)).
Selective reporting
We found no protocols for either study (Bülbül 2013; Ozturk
2011).
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We assessed Bülbül 2013 to have a low risk of reporting bias. The
outcomes listed in the methods section were all presented in the
results section although the study did not present any information
about adverse events.
We assessed Ozturk 2011 to be at a high risk of bias for selective
reporting. There appears to be a discrepancy between the adverse
events that were planned to be reported in the methods section
and the results section, which stated that “No clinically signifi-
cant adverse events were reported”. However, the paper follows
this statement by reporting a number of patients with increase in
appetite and weight gain, which were classified as “clinically sig-
nificant adverse events” in the methods section of the paper. No
information was provided about other types of adverse events and
we cannot be certain that there were no events. In addition, the
summed scores for the individual symptom scores as presented in
the paper do not add up to the total symptom score as presented
and no information is presented with regard to any adjustments
or weighting that may have been made.
Other potential sources of bias
Use of validated outcome measures
The validation of outcomes was one area of potential bias that we
identified as relevant at the start of the review. Bülbül 2013 did
not provide information regarding the validation of the outcome
measures. Similarly, Ozturk 2011 did not mention whether the
measures they used for assessing outcomes were validated and this
is particularly a concern when symptom severity was “... assessed
in the patients and their parents” using visual analogue scales.
Funding and conflict of interests in trials
No funding information was presented for either trial (Bülbül
2013; Ozturk 2011). With regards to conflicts of interest, Bülbül
2013 stated that there were “None declared” and Ozturk 2011 de-
clared that “The authors have declared that they have no conflicts
of interest”.
Baseline characteristics
Bülbül 2013 was a poorly reported study and did not present
details of the baseline characteristics for each group. There was a
non-significant difference between the groups for the severity of
nasal polyps, with the placebo group containing the more severely
affected patients. The small size of the trial makes it difficult to
draw conclusions.
The baseline characteristics for the two groups in Ozturk 2011
were similar with no significant differences between the groups
in any of the characteristics presented including age, duration of
symptoms or presence of atopy.
Effects of interventions
See: Summary of findings for the main comparison Short-
course oral corticosteroids compared to no oral corticosteroid
treatment (intranasal steroids in both groups) for chronic
rhinosinusitis; Summary of findings 2 Short-course oral
corticosteroids compared to placebo (antibiotics in both arms) for
chronic rhinosinusitis
Two trials comprising two different comparison pairs were in-
cluded in this review. Bülbül 2013 compared oral steroids with a
background of intranasal corticosteroids in 30 adults with chronic
rhinosinusitis and nasal polyps. Ozturk 2011 investigated oral
steroids with a background of antibiotics in 48 children with
chronic rhinosinusitis without nasal polyps. The results of these
two comparison pairs are discussed separately.
Where the range of scales and values for minimal important
differences were unclear, we used the standardised mean differ-
ence (SMD) as a guide to estimate the effect sizes. As suggested
in the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011), we used standard rules of thumb in the inter-
pretation of effect sizes (SMD, or Cohen’s effect size of < 0.41 =
small, 0.40 to 0.70 = moderate, > 0.70 = large) (Cohen 1988).
Oral steroids as an adjunct to intranasal
corticosteroids
See also Summary of findings for the main comparison.
Primary outcomes
1. Disease-specific health-related quality of life
The study did not report this as an outcome.
2. Disease severity - symptoms score
The study did not report this as an outcome. Individual symptom
scores were not reported.
3. Significant adverse effect: mood or behavioural
disturbances
The study did not report this as an outcome.
Secondary outcomes
1. General health-related quality of life
The study did not report this as an outcome.
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2. Other adverse event: gastrointestinal disturbances
The study did not report this as an outcome.
3. Other adverse event: insomnia
The study did not report this as an outcome.
4. Other adverse event: osteoporosis
The study did not report this as an outcome.
5. Endoscopic scores (including nasal polyps score)
Nasal polyps scores were measured after treatment (21 days) in
Bülbül 2013 using the Rasp criteria, although no explanation of,
or reference to, the criteria or validation thereof was made within
the paper. Further investigation into this scale appears to indicate
that the Rasp criteria rate the severity of nasal polyps on a four-
point scale (1 to 4, 1 = least severe) (Coˆ té 2011). The results
were available for 30 patients and showed that there might be an
improvement in mean nasal polyp size for the population that
received oral and intranasal steroids, compared with the group
receiving intranasal steroids alone (mean difference (MD) -0.46,
95% confidence interval (CI) -0.87 to -0.05) (Analysis 1.1). The
observed mean difference corresponds to a large effect size (SMD
of 0.79). This result is not presented in the ’Summary of findings’
table as we did not consider it to be a priority outcome.
6. Computerised tomography (CT) scan score
The study did not report this outcome.
Oral steroids as an adjunct to antibiotics
See also Summary of findings 2.
Primary outcomes
1. Disease-specific health-related quality of life
The study did not report this as an outcome.
2. Disease severity - symptoms score
Ozturk 2011 presented results for a total symptom score after
treatment (30 days) as assessed by patient and parents. The symp-
toms measured were purulent nasal discharge, nasal obstruction,
postnasal drainage, halitosis, cough and facial pain/headache using
a visual analogue scale (range of 0 to 10, 0 = “none”, 10 = “most
severe”). We combined the four individual scores that related to
elements of the EPOS 2012 diagnostic criteria (purulent nasal
discharge, nasal obstruction, cough and facial pain/headache) to
make a total symptom score with a range from 0 to 40 at the end
of treatment. Results for 45 children were available and showed a
lower score in the oral steroids group at 30 days (MD -7.10, 95%
CI -9.59 to -4.61) (Analysis 2.1). The observed mean difference
corresponds to a large effect size (SMD of 1.61).
Ozturk 2011 also presents results for individual symptom scores
for each of the four domains from the EPOS 2012 definition
criteria for chronic rhinosinusitis: purulent nasal discharge, nasal
obstruction, cough and facial pain or headache.
Nasal obstruction/congestion/blockage
Ozturk 2011 (45 participants) at the end of the trial (30 days)
showed an improvement in nasal blockage in favour of the group
receiving oral steroid and antibiotics compared with the group
that received antibiotics alone (MD -3.50, 95%CI -4.71 to -2.29)
(Analysis 2.2).
Nasal discharge
Ozturk 2011 measured ’purulent nasal discharge’ in 45 partic-
ipants and showed no improvement in discharge between the
groups at the end of the trial (MD -0.20, 95% CI -1.54 to 1.14)
(Analysis 2.3).
Facial pain or headache
Ozturk 2011 (45 participants) showed an improvement in facial
pain or headache in favour of the group with oral steroids in ad-
dition to antibiotics at the end of the trial (MD -1.30, 95% CI -
2.55 to -0.05) (Analysis 2.4).
Cough
Ozturk 2011 (45 participants) showed an improvement in cough
in favour of the oral steroid group at the end of the trial (MD -
2.10, 95% CI -3.35 to -0.85) (Analysis 2.5).
None of the results for individual symptoms are presented in the
GRADE ’Summary of findings’ table as we did not consider them
to be priority outcomes.
3. Significant adverse effect: mood or behavioural
disturbances
Ozturk 2011 states that “No clinically significant adverse events
were reported”, but does not provide further information for any
of the pre-specified adverse events in the protocol.
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Secondary outcomes
1. General health-related quality of life
The study did not report this as an outcome.
2. Other adverse event: gastrointestinal disturbances
Ozturk 2011 listed “gastrointestinal disturbances” as a “clinical sig-
nificant adverse event”. Although the report states that “No clini-
cally significant adverse events were reported”, the authors noted
that “increase in appetite” was reported in 16/24 patients in the
oral steroids and antibiotics group and 11/24 patients in the an-
tibiotics alone group. In addition, there was a larger “weight gain”
(which was also listed as “clinically significant adverse event”) re-
ported in the children receiving oral steroids and antibiotics com-
pared with those receiving antibiotics alone at the end of treatment
(30 days) (0.42 ± 0.26 kg and 0.27 ± 0.30 kg, respectively).
3. Other adverse event: insomnia
Ozturk 2011 states that “No clinically significant adverse events
were reported”, but it is uncertain whether there were any events
reported (see “gastrointestinal disturbances” above).
4. Other adverse event: osteoporosis
The study had not listed this as an outcome to be monitored or
reported.
5. Endoscopic scores (including nasal polyps score)
The study did not report this as an outcome.
6. Computerised tomography (CT) scan score
Ozturk 2011 reported the CT scan score at 30 days, as measured
using the Lund-Mackay scoring system (range: 0 to 24, higher =
more severe). The results (45 participants) showed an improve-
ment in CT score in favour of the oral steroid group at the end of
the trial (MD -2.90, 95% CI -4.91 to -0.89) (Analysis 2.6). This
is not presented in the GRADE ’Summary of findings’ table as we
did not consider it to be a priority outcome.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Short-course oral corticosteroids compared to placebo (antibiotics in both groups) for chronic rhinosinusitis
Patient or population: chronic rhinosinusit is
Setting: paediatric allergy and ENT department
Intervention: oral cort icosteroids and ant ibiot ics
Comparison: placebo and ant ibiot ics
Outcomes
No of participants (studies)
Anticipated absolute effects∗ (95% CI) Quality What happens
Without oral steroids With oral steroids Difference
Disease-specif ic health-re-
lated quality of lif e
No RCT reported this outcome
Disease severity - pat ient-
reported symptom score,
assessed with: 4 individual
symptoms measured on 0
to 10 visual analogue scale
summed to provide a range
of 0 to 40
Follow-up: 30 days 2
No. of part icipants: 45
(1 RCT)
The mean disease severity
score without oral steroids
was 15.2
The mean disease severity
score with oral steroids was
3.6
The mean disease sever-
ity score in the intervent ion
group was 7.10 lower (9.59
lower to 4.61 lower)
⊕⊕©©
LOW 1
A lower score indicates less severe
symptoms. The results relate to a stan-
dardised mean dif ference of 1.61 stan-
dard deviat ions lower (-2.29 to 0.93
lower), corresponding to a large dif fer-
ence
Adverse ef fect: mood or be-
havioural disturbances
No RCT reported this outcome
Health-related quality of lif e No RCT reported this outcome
Adverse ef fect: insomnia No RCT reported this outcome
Adverse ef fect: gastroin-
test inal disturbances
No RCT reported this outcome
2
1
S
h
o
rt-c
o
u
rse
o
ra
l
ste
ro
id
s
a
s
a
n
a
d
ju
n
c
t
th
e
ra
p
y
fo
r
c
h
ro
n
ic
rh
in
o
sin
u
sitis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Study completed only in children (mean age 8 years old). Study follow-up t ime was less than 3 months (1 month). Scales
were not validated and were completed by ‘‘parents and children’’.
2Symptoms included in this score were: purulent nasal discharge, nasal obstruct ion, cough and facial pain/ headache.
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D I S C U S S I O N
Summary of main results
The main findings of the review are as follows.
Short-course oral steroids as an adjunct to intranasal
corticosteroid treatment
One small study (30 adults with chronic rhinosinusitis with nasal
polyps) with a high risk of bias showed an improvement in nasal
polyp size (score measured by endoscopy) at 21 days for the group
receiving oral steroids and intranasal steroids, compared with the
group that received intranasal steroids alone. There were no data
available for any other efficacy outcome or adverse effects.
Short-course oral steroids as an adjunct to antibiotic
treatment
One small study (48 children, with chronic rhinosinusitis without
nasal polyps) showed an improvement in total symptom severity
score (low quality evidence) and computerised tomography (CT)
scan score with short-course oral steroids at one month for partic-
ipants who received oral steroids and antibiotics, compared with
those who received placebo tablets and antibiotics.
Overall completeness and applicability of
evidence
The evidence for oral steroids as an adjunct to other treatments
is incomplete. We identified only two small studies (78 partici-
pants) (Bülbül 2013; Ozturk 2011). Neither of them followed pa-
tients beyond the end of the treatment and thus they only reflect
the short-term outcomes of the treatment. There are no data on
whether the short-term benefits over just using intranasal corti-
costeroids or antibiotics are sustainable over the longer term.
The populations included within the trials were also limited; the
inclusion criteria for Bülbül 2013 were based solely on the diagno-
sis of nasal polyps. The severity of the other signs and symptoms
of chronic rhinosinusitis was unclear. We felt that the population
included in Ozturk 2011 was a very small, unusual group of the
chronic rhinosinusitis population, being childrenwith chronic rhi-
nosinusitis (well defined) but without the presence of nasal polyps.
The underlying pathology in children with chronic rhinosinusitis
is different from that in adults with nasal polyps.
The short time frame of evaluation (less than three months) in the
included studies also severely limits the completeness and appli-
cability of the evidence in this review.
Neither of the studies included in this review adequately reported
adverse effects, despite the adverse effects being one of the major
concerns with the use of this type of medication. This is a trend
repeated in other conditions and reliable data for adverse events
associated with short-term steroid use have not been well recorded
in the literature (Burton 2008).
Quality of the evidence
The quality of the evidence for polyp size measured by endo-
scopic score was very low for short-course oral corticosteroids
with intranasal steroids compared with intranasal steroids alone
(Summary of findings for the main comparison). We assessed the
quality as very low on account of serious risk of bias introduced by
the methodology of the trial (quasi-randomised, unblinded), the
very small study sample and the short-termnature of the outcomes
(21 days rather than three months).
For the comparison of short-course oral steroids with antibiotics
compared with antibiotics alone (Summary of findings 2), we as-
sessed the quality of the evidence as low.Therewere concerns about
whether disease severity was measured using a validated outcome,
the sample size was very small and we considered the directness
of the results of the trial to be reduced because of the short-term
nature of the outcomes (one month rather than three months).
Potential biases in the review process
Although many clinicians suggest that the typical maximum du-
ration for a short course of oral corticosteroids should 14 days,
we decided to use 21 days in the inclusion criteria for this review,
which is at the higher end of the acceptable duration. We still
considered the evidence for short courses up to 21 days to be rel-
evant and relaxing the inclusion criteria allowed more data to be
included. If we had limited the evidence to 14 days in this review,
we would have excluded both included studies. The studies had
used oral steroids for 15 and 21 days respectively (Bülbül 2013;
Ozturk 2011).
Validated symptom scores tomeasure patient-important outcomes
such as disease-specific health-related quality of life and disease
severity are often not used in chronic rhinosinusitis trials and we
identified this at the protocol stage as a potential bias (Chong
2015), which could affect the validity and interpretation of the
results. The problem is more serious for symptom scores used to
measure disease severity. Different trials measure different types
of chronic rhinosinusitis symptoms, often with more emphasis on
certain types of symptoms (e.g. asking a few questions related to
nasal discharge), by omitting certain types of symptoms, or both.
We had to make a decision on whether to exclude all of these data
(which is the majority of the data for disease severity across the
suite of reviews) (Chong 2016a; Chong 2016b; Chong 2016c;
Head2016a;Head2016b), or to try to distinguish scores that seem
valid (based on face validity) compared to those that do not. We
did this by making an assumption that if a scale is to be considered
as having face validity, it should measure symptoms relevant to
most chronic rhinosinusitis patients and not have symptoms that
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are not relevant to most chronic rhinosinusitis patients. Where a
study did not use a score that is known to be validated to mea-
sure disease severity in patients with chronic rhinosinusitis and the
study report did not provide information that suggested the score
had been validated, we included the total symptom score reported
in our analysis if at least two of the of the symptoms identified
in the EPOS 2012 diagnostic criteria for chronic rhinosinusitis
were measured, i.e. nasal blockage, nasal discharge, facial pain or
pressure, and loss of sense of smell (for adults) or cough (for chil-
dren). However, when a study included other symptoms, we tried
to exclude those and only included the scores for the main chronic
rhinosinusitis symptoms. For Ozturk 2011, we used the sum of
scores of four chronic rhinosinusitis symptoms rather than the to-
tal symptom score reported for two main reasons: the total score
reported in the study included items that may not be relevant to
chronic rhinosinusitis patients and there were discrepancies (i.e.
errors) in the total score at endpoint compared with a summation
of the individual scores. To account for the lack of validated scales
used and lack of validated methods to sum the scores, we down-
graded all the disease severity outcomes for lack of use of validated
scales whenever this occurred.
Agreements and disagreements with other
studies or reviews
Neither of the included studies in this review were included in
the previous Cochrane review on this subject (Martinez-Devesa
2011). The EPOS 2012 document included one of the studies,
Ozturk 2011, to provide evidence for the use of antibiotics and
combination treatment in children with chronic rhinosinusitis,
but did not include Bülbül 2013 (which was published after the
guideline).
Both of the studies in this review only presented short-term data
and the longest duration of follow-up was 30 days. As part of this
suite of chronic rhinosinusitis Cochrane reviews, we have investi-
gated the use of short-course oral steroids alone for chronic rhi-
nosinusitis (Head 2016a). This review concluded that, in general,
health-related quality of life and patient-reported symptoms were
improved with short-course oral steroids compared with placebo
or no treatment during the treatment period (14 to 21 days).How-
ever, these improvements in results were not sustained after the
course of oral steroid treatment had finished. The results for the
outcomes in the treatment and control groups showed no conclu-
sive results for any of the efficacy outcomes at three to six months
after treatment. This review did find limited evidence for three of
the pre-specified adverse events: mood disturbances, insomnia and
gastrointestinal disturbances. Of these, there was moderate quality
evidence of increases in insomnia and gastrointestinal disturbances
in the group given oral steroids compared with the comparison
group. The evidence for mood disturbances was less conclusive
(low quality) and there was no evidence of osteoporosis in any of
the studies.
As the included studies did not report the incidence of adverse
events and the risk of side effects may vary according to the con-
dition that they are used to treat, it is important to consider data
from similar conditions where possible. A recent review of sys-
temic steroids in acute rhinosinusitis identified five trials includ-
ing 1193 participants, receiving either oral steroids (prednisolone
at dosages ranging from 24 mg to 80 mg for three to seven days)
or placebo, where adverse events were reported (Venekamp 2014;
Venekamp 2015). There was no difference between the active and
control arms in terms of the risk of adverse events, with respect to
mild or severe events, or the risk of discontinuation of treatment.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence identified for this question is of low or very low qual-
ity. There is a high risk of bias within the trials due tomethodolog-
ical problems and many of the primary and secondary outcomes
(including adverse effects) were not reported well. In addition, the
short time frame of evaluation (less than three months) and the
variation in populations studied mean that there is a lack of high
quality evidence to be able to determine whether a short course of
oral steroids is beneficial to patients with chronic rhinosinusitis on
top of other treatment (such as intranasal steroids or antibiotics).
Implications for research
As of August 2015 there is very sparse information about the
efficacy of using oral steroids as an adjunct to other treatment (such
as intranasal steroids or antibiotics) and the associated adverse
events. This question remains relevant and important.
In addition to a trial of the efficacy of oral corticosteroids as an
adjunct to other treatment, aspects that need further investigation
include the timing of administration of oral steroids and the safety
of using multiple courses.
The trial should include patients with chronic rhinosinusitis di-
agnosed using the EPOS 2012 criteria and include both patients
with and without nasal polyps (stratified randomisation by sub-
group). The trial should compare a short course of oral steroids
with placebo where all patients in both arms are receiving clini-
cally relevant doses of other treatment (such as intranasal corticos-
teroids). Oral steroids should be given for between one and three
weeks at an appropriate dose. The primary outcomes should in-
clude the important patient-reported outcomes (such as disease-
specific health-related quality of life and disease severity) assessed
using validated measures. Endoscopic evaluation should not be
chosen as a primary outcome because the correlation between en-
doscopic results and patient symptoms is unclear. Adverse events
should be defined in the protocol and measured during treatment
and in the follow-up period.
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In addition tomeasuring outcomes at the end of oral corticosteroid
treatment, future trials should follow up patients and measure
outcomes for at least six months.
This review is one of a suite of reviews of medical treatments for
chronic rhinosinusitis, each of which features its own research rec-
ommendations. Across all reviews, key features of future research
are as follows:
• Trials should be adequately powered and imbalances in
prognostic factors (for example, prior sinus surgery) must be
accounted for in the statistical analysis.
• Study participants should be diagnosed with chronic
rhinosinusitis using the EPOS 2012 criteria and should
primarily be recruited based on their symptoms. Different
patient phenotypes (that is, those with and without nasal polyps)
should be recognised and trials should use stratified
randomisation within these subgroups or focus on one or other
of the phenotypes.
• Studies should focus on outcomes that are important to
patients and use validated instruments to measure these.
Validated chronic rhinosinusitis-specific health-related quality of
life questionnaires exist, for example the Sino-Nasal Outcome
Test-22 (SNOT-22). Patients may find dichotomised outcomes
easiest to interpret; for example the percentage of patients
achieving a minimal clinically important difference (MCID) or
improvement for that outcome. Such MCIDs or cut-off points
should be included in the study protocol and clearly outlined in
the methods section.
• Trials and other high-quality studies should use consistent
outcomes and adhere to reporting guidelines, such as
CONSORT, so that results can be compared across future trials.
The development of a standardised set of outcomes, or core
outcome set, for chronic rhinosinusitis, agreed by researchers,
clinicians and patients, will facilitate this process.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bülbül 2013
Methods 3-arm, non-blinded, parallel-group, with 21 days duration of treatment and follow-up
Participants Location: Turkey, 1 site
Setting of recruitment and treatment: ear, nose and throat department of Haydarpasa
Numune education and research hospital, Istanbul
Sample size: 45
Number randomised (and completed): 15 in oral steroids and INCS, 15 in INCS alone,
15 in oral steroids alone (see notes below)
Participant (baseline) characteristics:
• Mean age (SD): 34.7 ± 16.72 years (average for all 3 groups)
• Gender (male/female): 25/20 (across all 3 groups)
• Main diagnosis: volunteers who received a diagnosis of nasal polyposis
• Polyps status: 100% with polyps
• Polyp grade n (%):
- Grade 1: oral steroids and INCS: 1 (6.7%); INCS alone: 3 (13.3%)
- Grade 2: oral steroids and INCS: 9 (60%); INCS alone: 5 (33.3%)
- Grade 3: oral steroids and INCS: 5 (33.3%); INCS alone: 8 (53.3%)
• Previous sinus surgery status: no information
• Previous courses of steroids: no information
• Positive skin prick test: INCS alone: 7; oral steroids and INCS: 6
Inclusion criteria: none stated. No information on polyp grading criteria (other than
Rasp)
Exclusion criteria: patients in whom corticosteroid therapy was contraindicated (i.
e. those with diabetes mellitus, hypertension, glaucoma, a history of tuberculosis or
emotional instability), as well as those who had received corticosteroids within the last
month
Interventions Oral steroids and INCS (n = 15): oral methylprednisolone, 1 mg/kg and reduced
progressively over a 21-day treatment course
INCS alone (n = 15): no oral steroid treatment
Use of additional interventions (common to both treatment arms): budesonide,
unclear method of administration except it states ’intranasal’, 400 µg/day, 21 days
Outcomes Primary outcomes: none reported
Secondary outcomes:
• Polyps size: measured by endoscopic appearance and staging according to the
Rasp Classification (1 to 4, 1 = least severe) at 21 days
Other outcomes reported by the study:
• Measurement of nitric oxide levels
Funding sources No information provided
Declarations of interest “None declared”
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Bülbül 2013 (Continued)
Notes The trial is a 3-arm trial comparing “oral steroids alone”, “INCS alone” and “oral steroids
and INCS”. The results for the “oral steroids alone” group are not presented here as they
are not relevant to this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Patients were allocated in turn to
either the first, second or third treatment
group, depending on their order of presen-
tation.”
Comment: pg 585, col 1, para 4
Allocation concealment (selection bias) High risk Comment: as randomisation was com-
pleted based on order of presentation, there
is a high risk of bias due to allocation con-
cealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: the study was not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: there is no information regard-
ing blinding of outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no patients dropped out of the
study
Selective reporting (reporting bias) Low risk Comment: all outcomes are reported
Other bias Unclear risk Comment: Rasp classification used for en-
doscopic polyp staging. Unclear whether
this has been validated and no details on
stage used
Baseline characteristics are not well de-
scribed but the polyp grade seems to be
unevenly distributed (although not statisti-
cally significant) with more severe patients
in the placebo group, which may have af-
fected the results. The small size of the trial
makes it difficult to draw conclusions
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Ozturk 2011
Methods 2-arm, double-blind, parallel-group RCT, with 15-day duration of oral steroid treatment
and 30-day duration of follow-up
Participants Location: Turkey, 2 sites
Setting of recruitment and treatment: paediatric allergy and ear, nose, and throat
outpatient clinics of 2 university hospitals
Sample size: 48
Number randomised: 24 in oral steroids and antibiotics, 24 in antibiotics alone
Number completed: 22 in intervention, 23 in antibiotics alone
Participant (baseline) characteristics: note: no. analysed not randomised
• Mean age (SD): oral steroids and antibiotics: 8.5 (2.9); antibiotics alone: 8.0 (2.3)
• Gender (M/F): oral steroids and antibiotics: 14/8 antibiotics alone: 15/8
• Main diagnosis: children with chronic rhinosinusitis
• Polyps status: 0% with polyps
• Previous sinus surgery status: no information
• Previous courses of steroids: information not provided
• Atopy: oral steroids and antibiotics: 8 (36%); antibiotics alone: 10 (43%)
Inclusion criteria: children with CRS; CRS diagnosis made on a basis of sinonasal
symptoms and signs present for a period of more than 3 months in the presence of ab-
normalities on coronal sinus computed tomographic (CT) scans. All patients presented
with nasal purulence, postnasal purulence or both and 1 or more of the following symp-
toms: nasal obstruction, cough, halitosis, headache or facial pain/pressure. They had
multiple courses (each 10 to 14 days, > 3 courses) of antimicrobial treatment with at
least 2 or more of the following broad-spectrum antibiotics before entry into the study:
amoxicillin-clavulanic acid, second-generation cephalosporins (mostly cefuroxime) or
clarithromycin
Patients with allergic rhinitis were also included if they also showed purulent rhinorrhoea,
postnasal purulence or both
Exclusion criteria:
- Systemic corticosteroids in the last 2 months before the study
- Systemic antibiotics and inhaler or intranasal corticosteroids in the last 4 weeks before
the study
- Other respiratory tract disorders (cystic fibrosis, ciliary dyskinesia, nasal polyps, large
adenoids and asthma), immune deficiency
- Systemic disease, gastroesophageal reflux, aspirin sensitivity
- Acquired or congenital sinonasal abnormalities, contraindication to corticosteroid use
- Patients with pollen-induced rhinitis if they were seen during the pollen season
Interventions Intervention (n = 24): oral methylprednisolone tablets, 15 days according to the fol-
lowing schedule (doses were rounded up to the nearest 4 mg):
- 1 mg/kg/day (maximum, 40 mg/day) for 10 days
- 0.75 mg/kg/day for 2 days, 0.5 mg/kg/day for 2 days
- 0.25 mg/kg/day for 1 day
Comparator group (n = 24): placebo tablets for 15 days
Use of additional interventions (common to both treatment arms): antibiotics (oral
amoxicillin/clavulanate) was administered at 45/6.4 mg/kg/day (maximum, 2000/285
mg/day) for 30 days
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Ozturk 2011 (Continued)
Outcomes Primary outcomes:
1. Disease severity, assessed by the patients and their parents by using a visual analogue
scale (VAS) (range 0 (no symptoms) to 10 (most severe)). The symptoms scored were:
purulent nasal discharge, nasal obstruction, postnasal drainage, halitosis, cough, and fa-
cial pain or headache. Individual scores were combined to make a rhinosinusitis symp-
tom score (range 0 to 60) at the end of treatment measured at 30 days
Secondary outcomes:
2. CT scan, scored using the Lund-Mackay staging system (0 to 24) measured at 30 days
Other outcomes reported by the study:
• Compliance
• Clinical recovery (definition in paper)
• Relapse (definition in paper)
• “Tolerability was evaluated by means of medical history, physical examination,
and measurement of adverse events. Hypertension, edema, weight gain, increase in
appetite, gastrointestinal disturbances, nervousness, agitation, psychosis, headache,
mood swings, delirium, euphoria, moon face, skin atrophy, bruising,
hyperpigmentation, muscle weakness, joint pain, and allergic reactions were defined as
clinically significant adverse events”
Funding sources No information provided
Declarations of interest “The authors have declared that they have no conflicts of interest.”
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “…a randomallocation chart based
on a table of random numbers.”
Comment: pg 349, col 2, para 1
Allocation concealment (selection bias) Low risk Quote: “Randomization assignments were
kept in sealed envelopes”
Comment: pg 349, col 2, para 1
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Placebo tablets contained lactose
and were of same size and colour as methyl-
prednisolone (16 mg per tablet). Placebo
and methylprednisolone tablets were dis-
pensed in identical packets containing a
minimum of 20 tablets each.”
“The randomization code was kept by the
nursing staff in the pediatric allergy depart-
ment.”
Comment: pg 349, col 2, para 1
Although the paper states that the tablets
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Ozturk 2011 (Continued)
were equivalent with respect to size and
colour, no mention was made about the
taste of the tablets. As the taste of methyl-
prednisolone is different to lactose, it may
have been obvious which was the treat-
ment. 1 patient in the treatment group
dropped out due to unpalatability
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: the study reports that the par-
ticipants were blinded and so the patient-
reported outcomes are likely to have been
blinded. For the CT scan outcome it is
noted that the assessor was blind to treat-
ment and sequence
No mention of whether the analysis was
completed blind.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: although there was low drop-
out (3/48 = 6%) there are no clear reasons
provided for 2 of the patients’ “protocol vi-
olation” or why their results were not in-
cluded in the analysis
Selective reporting (reporting bias) High risk Quote: “No clinically significant adverse
events were reported. Twenty seven parents
(16 in the methylprednisolone group and
11 in the placebo group) reported that their
children’s appetite and weight increased af-
ter treatment. At the end of the treatment,
themean ± SD changes in patients’ weights
from baseline were 0.42 ± 0.26 kg in the
methylprednisolone group versus 0.27 ± 0.
30 kg in the placebo group. The difference
was not significant (P = 0.08)”
Comment: although all of the efficacy out-
comes are presented in the results section,
the methods section classified increase in
appetite and weight gain as clinically sig-
nificant adverse events and the results in-
dicated that there may be a difference be-
tween the groups
The summed scores for the individual
symptom scores as presented in the paper
do not add up to the total symptom score
as presented
Other bias Unclear risk Comment: no information regarding the
validation of visual analogue scales for
reporting CRS symptoms. Nothing was
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Ozturk 2011 (Continued)
made in the results of the finding that the
placebo group benefited substantially from
placebo treatment
CRS: chronic rhinosinusitis
CT: computerised tomography
INCS: intranasal steroids
RCT: randomised controlled trial
SD: standard deviation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alobid 2005 INTERVENTION: oral steroids versus surgery
Alobid 2006 INTERVENTION: oral steroids alone versus no steroid treatment
Alobid 2012 INTERVENTION: oral steroids alone versus no steroid treatment
Alobid 2014 INTERVENTION: oral steroids alone versus no steroid treatment
Benitez 2006 INTERVENTION: oral steroids alone versus no steroid treatment
Blomqvist 2001 INTERVENTION: surgery
Blomqvist 2009 INTERVENTION: combined medical and surgical treatment
Bonfils 1998 STUDY DESIGN: not randomised
Bonfils 2003 STUDY DESIGN: not randomised
Bonfils 2006 STUDY DESIGN: not randomised
Chi 2011 INTERVENTION: oral steroid alone versus placebo
(Ongoing study)
Chi Chan 1996 STUDY DESIGN: not randomised
Damm 1999 INTERVENTION: oral steroid (12 days) + INCS versus oral steroid (20 days) + INCS
Ecevit 2015 INTERVENTION: oral steroids alone versus placebo
Grammer 2013 STUDY DESIGN: review of previous oral steroids trials
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(Continued)
Hessler 2007 STUDY DESIGN: not randomised
Hissaria 2006 INTERVENTION: oral steroids alone versus placebo
Jankowski 2003a STUDY DESIGN: not randomised
Jankowski 2003b STUDY DESIGN: not randomised
Kapucu 2012 INTERVENTION: 4-arm trial: (1) oral steroids, (2) intranasal steroids, (3) steroid injection into polyp, (4)
no treatment
Kirtsreesakul 2011 INTERVENTION: oral steroid alone then INCS versus placebo then INCS (note: oral steroids and INCS
not given concurrently)
Kirtsreesakul 2012 INTERVENTION: oral steroid alone then INCS versus placebo then INCS (note: oral steroids and INCS
not given concurrently)
Kroflic 2006 INTERVENTION: endoscopic polypectomy with ethmoidectomy
Lildholdt 1988 INTERVENTION: surgical removal versus systemic corticosteroids
Lildholdt 1989 INTERVENTION: surgical polypectomy followed by continuous topical steroid treatment versus a single
dose of depot steroid
Martinez-Anton 2008 INTERVENTION: oral steroids alone versus no steroid treatment
NCT00841802 INTERVENTION: oral steroids alone versus no steroid treatment
(Ongoing study)
NCT02367118 INTERVENTION: oral steroids alone versus placebo
(Ongoing study)
Nores 2003 STUDY DESIGN: not randomised
Ragab 2006 INTERVENTION: medical versus surgical treatment
Rasp 1997 STUDY DESIGN: not randomised
Rasp 2000 STUDY DESIGN: not randomised
Remer 2005 STUDY DESIGN: not randomised
Reychler 2015 INTERVENTION: oral steroid versus INCS
Rupa 2010 POPULATION: allergic fungal sinusitis
Sieskiewicz 2006 STUDY DESIGN: surgical outcomes paper
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(Continued)
Sousa 2009 STUDY DESIGN: not randomised
Stevens 2001 STUDY DESIGN: not randomised
Tuncer 2003 STUDY DESIGN: not randomised
Vaidyanathan 2011 INTERVENTION: oral steroids alone then INCS versus placebo then INCS (note: oral steroids and INCS
not given concurrently)
van Camp 1994 STUDY DESIGN: not randomised
Van Zele 2008 INTERVENTION: oral steroids alone then INCS versus placebo then INCS (note: oral steroids and INCS
not given concurrently)
Van Zele 2010 INTERVENTION: oral steroids alone then INCS versus placebo then INCS (note: oral steroids and INCS
not given concurrently)
INCS: intranasal steroids
Characteristics of ongoing studies [ordered by study ID]
NCT01676415
Trial name or title Corticosteroid therapy for chronic rhinosinusitis without nasal polyps (CRSsNP)
Methods 2-arm, randomised, controlled, parallel-group, open study
Participants 40 patients (18 to 80 years old) with CRS without nasal polyps
Interventions Group 1: systemic prednisone: starting dose of 40 mg for 5 days followed by a taper decreasing by 10 mg
every 5 days. Followed by topical mometasone (INCS) until the end of the study
Group 2: topical mometasone (INCS) at the standard dose of 2 sprays into each nostril once daily until the
end of the study
Both groups: 3-week course of a broad-spectrum antibiotic, amoxicillin/clavulanate, at a daily dose of 875
mg twice daily. If the participant is allergic to penicillin and its derivatives or has had an adverse reaction to
amoxicillin/clavulanate, a 3-week course of clarithromycin instead
Outcomes Primary: Lund-MacKay score from CT scan
Secondary: Taskforce symptom inventory, SNOT-22 questionnaire, medication side effects and compliance
inventory
All outcomes measured at 4 to 6 weeks and 3 months after initiation of treatment
Starting date August 2012
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NCT01676415 (Continued)
Contact information Bruce Tan, MD, Assistant Professor, Dept of Otolaryngology, Northwestern University Feinberg School of
Medicine (contact: caroline.price@northwestern.edu)
Notes Results expected June 2017
CRS: chronic rhinosinusitis
CT: computerised tomography
INCS: intranasal corticosteroids
SNOT-22: Sino-Nasal Outcome Test-22
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D A T A A N D A N A L Y S E S
Comparison 1. Oral corticosteroids versus no treatment (intranasal steroids in both groups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Nasal polyp grading 1 30 Mean Difference (IV, Fixed, 95% CI) -0.46 [-0.87, -0.05]
Comparison 2. Oral corticosteroids versus placebo (antibiotics in both arms)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total symptom score 1 45 Mean Difference (IV, Fixed, 95% CI) -7.10 [-9.59, -4.61]
2 Nasal obstruction 1 45 Mean Difference (IV, Fixed, 95% CI) -3.50 [-4.71, -2.29]
3 Purulent nasal discharge 1 45 Mean Difference (IV, Fixed, 95% CI) -0.20 [-1.54, 1.14]
4 Headache/facial pain 1 45 Mean Difference (IV, Fixed, 95% CI) -1.3 [-2.55, -0.05]
5 Cough 1 45 Mean Difference (IV, Fixed, 95% CI) -2.10 [-3.35, -0.85]
6 CT score 1 45 Mean Difference (IV, Fixed, 95% CI) -2.90 [-4.91, -0.89]
Analysis 1.1. Comparison 1 Oral corticosteroids versus no treatment (intranasal steroids in both groups),
Outcome 1 Nasal polyp grading.
Review: Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis
Comparison: 1 Oral corticosteroids versus no treatment (intranasal steroids in both groups)
Outcome: 1 Nasal polyp grading
Study or subgroup
Oral
steroids
with INCS INCS alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bu¨lbu¨l 2013 15 1.67 (0.49) 15 2.13 (0.64) 100.0 % -0.46 [ -0.87, -0.05 ]
Total (95% CI) 15 15 100.0 % -0.46 [ -0.87, -0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours OCS + INCS Favours INCS alone
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Analysis 2.1. Comparison 2 Oral corticosteroids versus placebo (antibiotics in both arms), Outcome 1 Total
symptom score.
Review: Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis
Comparison: 2 Oral corticosteroids versus placebo (antibiotics in both arms)
Outcome: 1 Total symptom score
Study or subgroup
Oral steroids
+ antibiotics Placebo + antibiotics
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ozturk 2011 22 3.6 (2.46) 23 10.7 (5.55) 100.0 % -7.10 [ -9.59, -4.61 ]
Total (95% CI) 22 23 100.0 % -7.10 [ -9.59, -4.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.59 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours oral steroids Favours placebo
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Analysis 2.2. Comparison 2 Oral corticosteroids versus placebo (antibiotics in both arms), Outcome 2
Nasal obstruction.
Review: Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis
Comparison: 2 Oral corticosteroids versus placebo (antibiotics in both arms)
Outcome: 2 Nasal obstruction
Study or subgroup
Oral steroids
+ antibiotics Placebo + antibiotics
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ozturk 2011 22 0.3 (0.6) 23 3.8 (2.9) 100.0 % -3.50 [ -4.71, -2.29 ]
Total (95% CI) 22 23 100.0 % -3.50 [ -4.71, -2.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.66 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours oral steroids Favours placebo
Analysis 2.3. Comparison 2 Oral corticosteroids versus placebo (antibiotics in both arms), Outcome 3
Purulent nasal discharge.
Review: Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis
Comparison: 2 Oral corticosteroids versus placebo (antibiotics in both arms)
Outcome: 3 Purulent nasal discharge
Study or subgroup
Oral steroids
+ antibiotics Placebo + antibiotics
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ozturk 2011 22 2.1 (1.8) 23 2.3 (2.7) 100.0 % -0.20 [ -1.54, 1.14 ]
Total (95% CI) 22 23 100.0 % -0.20 [ -1.54, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours oral steroids Favours placebo
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Analysis 2.4. Comparison 2 Oral corticosteroids versus placebo (antibiotics in both arms), Outcome 4
Headache/facial pain.
Review: Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis
Comparison: 2 Oral corticosteroids versus placebo (antibiotics in both arms)
Outcome: 4 Headache/facial pain
Study or subgroup
Oral steroids
+ antibiotics Placebo + antibiotics
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ozturk 2011 22 0.5 (1.2) 23 1.8 (2.8) 100.0 % -1.30 [ -2.55, -0.05 ]
Total (95% CI) 22 23 100.0 % -1.30 [ -2.55, -0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.04 (P = 0.041)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours oral steroids Favours placebo
Analysis 2.5. Comparison 2 Oral corticosteroids versus placebo (antibiotics in both arms), Outcome 5
Cough.
Review: Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis
Comparison: 2 Oral corticosteroids versus placebo (antibiotics in both arms)
Outcome: 5 Cough
Study or subgroup
Oral steroids
+ antibiotics Placebo + antibiotics
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ozturk 2011 22 0.7 (1.4) 23 2.8 (2.7) 100.0 % -2.10 [ -3.35, -0.85 ]
Total (95% CI) 22 23 100.0 % -2.10 [ -3.35, -0.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.30 (P = 0.00098)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours oral steroids Favours placebo
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Analysis 2.6. Comparison 2 Oral corticosteroids versus placebo (antibiotics in both arms), Outcome 6 CT
score.
Review: Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis
Comparison: 2 Oral corticosteroids versus placebo (antibiotics in both arms)
Outcome: 6 CT score
Study or subgroup
Oral steroids
+ antibiotics Placebo + antibiotics
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ozturk 2011 22 1.2 (2.8) 23 4.1 (4) 100.0 % -2.90 [ -4.91, -0.89 ]
Total (95% CI) 22 23 100.0 % -2.90 [ -4.91, -0.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.83 (P = 0.0047)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours oral steroids Favours placebo
A D D I T I O N A L T A B L E S
Table 1. Summary of the most commonly reported side effects of systemic steroids
System Adverse events Notes
Musculoskeletal Osteoporosis Largely limited to long-term use
Significantly increased risk of fractures with prolonged use
Osteonecrosis Rare; appears to be dose-dependent
Endocrine Hyperglycaemia Common; dose-dependent, usually reversible
Cardiovascular Hypertension Common; dose-dependent, usually reversible
Dermatological Striae, bruising Dose-dependent, occurs after > 1 month usage
Ophthalmological Cataracts Irreversible; largely related to long-term usage
Glaucoma High risk with pre-existing disease
Gastrointestinal tract Peptic ulceration Increased risk largely due to concomitant NSAIDs
Psychological Psychosis Common; increased risk with dosages > 40 mg/day
References: Da Silva 2006; Naber 1996; Stanbury 1998
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NSAIDs: non-steroidal anti-inflammatory drugs
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL Ovid MEDLINE
#1 MeSH descriptor: [Sinusitis] explode all trees
#2 MeSH descriptor: [Rhinitis] this term only
#3 MeSH descriptor: [Rhinitis, Atrophic] this term only
#4 MeSH descriptor: [Rhinitis, Vasomotor] this term only
#5 MeSH descriptor: [Paranasal Sinus Diseases] this term only
#6 MeSH descriptor: [Paranasal Sinuses] explode all trees
#7 rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
sphenoiditis
#8 kartagener* near syndrome*
#9 inflamm* near sinus*
#10 (maxilla* or frontal*) near sinus*
#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
#12 MeSH descriptor: [Chronic Disease] explode all trees
#13 MeSH descriptor: [Recurrence] explode all trees
#14 chronic or persis* or recurrent*
#15 #12 or #13 or #14
#16 #11 and #15
#17 CRSsNP
#18 (sinusitis or rhinitis) near (chronic or persis* or recurrent*)
#19 #16 or #17 or #18
#20 MeSH descriptor: [Nasal Polyps] explode all trees
#21 MeSH descriptor: [Nose] explode all trees
#22 MeSH descriptor: [Nose Diseases] explode all trees
#23 #21 or #22
#24 MeSH descriptor: [Polyps] explode all trees
#25 #23 and #24
#26 (nose or nasal or rhino* or rhinitis or sinus* or sinonasal) near
(papilloma* or polyp*)
#27 rhinopolyp* or CRSwNP
#28 #19 or #20 or #25 or #26 or #27
#29 MeSH descriptor: [Steroids] explode all trees
#30 MeSH descriptor: [Adrenal Cortex Hormones] explode all
trees
#31 MeSH descriptor: [Glucocorticoids] explode all trees
#32 MeSH descriptor: [Anti-Inflammatory Agents] explode all
trees
1 exp Sinusitis/
2 paranasal sinus diseases/ or rhinitis/ or rhinitis, atrophic/ or
rhinitis, vasomotor/
3 exp Paranasal Sinuses/
4 (rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
sphenoiditis).ab,ti
5 (kartagener* adj3 syndrome*).ab,ti.
6 (inflamm* adj5 sinus*).ab,ti.
7 ((maxilla* or frontal*) adj3 sinus*).ab,ti.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp chronic disease/
10 exp Recurrence/
11 (chronic or persis* or recurrent*).ab,ti.
12 9 or 10 or 11
13 8 and 12
14 CRSsNP.ab,ti.
15 ((sinusitis or rhinitis) adj3 (chronic or persis* or recurrent*)).
ab,ti
16 13 or 14 or 15
17 exp Nasal Polyps/
18 exp Nose/ or exp Nose Diseases/
19 exp Polyps/
20 18 and 19
21 ((nose or nasal or rhino* or rhinitis or sinus* or sinonasal) adj3
(papilloma* or polyp*)).ab,ti
22 (rhinopolyp* or CRSwNP).ab,ti.
23 16 or 17 or 20 or 21 or 22
24 exp Steroids/
25 exp Adrenal Cortex Hormones/
26 exp Glucocorticoids/
27 exp Anti-Inflammatory Agents/
28 exp Anti-Inflammatory Agents, Non-Steroidal/
29 27 not 28
30 (steroid* or glucocorticoid* or corticosteroid* or glucos-
teroid* or cyclocosteroid* orbeclomethasone or beclometasone or
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(Continued)
#33 MeSH descriptor: [Anti-Inflammatory Agents, Non-
Steroidal] explode all trees
#34 #32 not #33
#35 steroid* or glucocorticoid* or corticosteroid* or glucosteroid*
or cyclocosteroid*
#36 beclomethasone or beclometasone or beclamet or beclocort
or becotide
#37 betamethasone or betadexamethasone or flubenisolone or ce-
leston* or cellestoderm or betnelan or oradexon
#38 dexamethasoneor dexameth or dexone or dexametasone or
decadron or dexasone or hexadecadron or hexadrol or methylflu-
orprednisolone or millicorten
#39 flunisolide or fluticasone or hydrocortisone or cortisol or cor-
tifair or cortril or hyrocortone or cortef or epicortisol or efcortesol
or Cortisone
#40 methylprednisolone or medrol or metripred or urbason
#41 mometasone or prednisolone or precortisyl or deltacortril or
deltastab or prednesol or deltasone or prednisone or cortan or
liquid next pred or meticorten
#42 paramethasone or triamcinolone or aristocort or volon or
atolone or kenacort or orasone or panasol or prednicen
#43 corticoid* or betamethason* or betamethasone or hydrocorti-
son* or celesto* or dexamethason* or hexadecadrol or budesonid*
or horacort or pulmicort or rhinocort or methylfluorprednisolone
or flunisolid* or nasalide or fluticason* or flonase or flounce or
mometason* or nasonex or triamclinolon* or nasacort or tri next
nasal or aristocort or Ciclesonide
#44 #29 or #30 or #31 or #34 or #35 or #36 or #37 or #38 or #
39 or #40 or #41 or #42 or #43
#45 #28 and #44
beclamet or beclocort or becotide or betamethasone or betadexam-
ethasone or flubenisolone or celeston* or cellestoderm or betnelan
or oradexon or dexamethasone or dexameth or dexone or dexam-
etasone or decadron or dexasone or hexadecadron or hexadrol or
methylfluorprednisolone or millicorten or flunisolide or fluticas-
one or hydrocortisone or cortisol or cortifair or cortril or hyrocor-
tone or cortef or epicortisol or efcortesol or Cortisone or methyl-
prednisolone or medrol or metripred or urbason or mometasone
or prednisolone or precortisyl or deltacortril or deltastab or pred-
nesol or deltasone or prednisone or cortan or liquid next pred
or meticorten or paramethasone or triamcinolone or aristocort or
volon or atolone or kenacort or orasone or panasol or prednicen)
.ab,ti
31 (corticoid* or betamethason* or betamethasone or hydrocorti-
son* or celesto* or dexamethason* or hexadecadrol or budesonid*
or horacort or pulmicort or rhinocort or methylfluorprednisolone
or flunisolid* or nasalide or fluticason* or flonase or flounce or
mometason* or nasonex or triamclinolon* or nasacort or (tri adj3
nasal) or aristocort or Ciclesonide).ab,ti
32 24 or 25 or 26 or 29 or 30 or 31
33 23 and 32
Ovid EMBASE Trial registries (via CRS)
1 exp sinusitis/ or paranasal sinus disease/
2 atrophic rhinitis/ or chronic rhinitis/ or rhinosinusitis/ or vaso-
motor rhinitis/
3 exp paranasal sinus/
4 (rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
sphenoiditis).tw
5 (kartagener* adj3 syndrome*).tw.
6 (inflamm* adj5 sinus*).tw.
7 ((maxilla* or frontal*) adj3 sinus*).tw.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp chronic disease/
10 exp recurrent disease/
11 (chronic or persis* or recurrent*).tw.
12 9 or 10 or 11
13 8 and 12
14 CRSsNP.tw.
ClinicalTrials.gov
Condition: rhinitis OR sinusitis OR rhinosinusitis OR (nose
AND polyp*) OR (nasal AND polyp*) OR CRSsNP OR CR-
SwNP OR CRS
ICTRP
Title: rhinitis OR sinusitis OR rhinosinusitis OR CRSsNP OR
CRSwNP OR CR
OR
All: (nose AND polyp*) OR (nasal AND polyp*)
NB These searches were run from 1 March 2015 to 11 August 2015,
when these terms were last searched to populate the Cochrane ENT
trials register in CRS
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(Continued)
15 ((sinusitis or rhinitis) adj3 (chronic or persis* or recurrent*)).
tw
16 13 or 14 or 15
17 exp nose polyp/
18 exp nose disease/ or exp nose/
19 exp polyp/
20 18 and 19
21 ((nose or nasal or rhino* or rhinitis or sinus* or sinonasal) adj3
(papilloma* or polyp*)).tw
22 (rhinopolyp* or CRSwNP).tw.
23 16 or 17or 20 or 21 or 22
24 exp *corticosteroid/
25 exp steroid/
26 exp antiinflammatory agent/
27 exp nonsteroid antiinflammatory agent/
28 26 not 27
29 (steroid* or glucocorticoid* or corticosteroid* or glucos-
teroid* or cyclocosteroid* or beclomethasone or beclometasone or
beclamet or beclocort or becotide or betamethasone or betadexam-
ethasone or flubenisolone or celeston* or cellestoderm or betnelan
or oradexon or dexamethasone or dexameth or dexone or dexam-
etasone or decadron or dexasone or hexadecadron or hexadrol or
methylfluorprednisolone or millicorten or flunisolide or fluticas-
one or hydrocortisone or cortisol or cortifair or cortril or hyrocor-
tone or cortef or epicortisol or efcortesol or Cortisone or methyl-
prednisolone or medrol or metripred or urbason or mometasone
or prednisolone or precortisyl or deltacortril or deltastab or pred-
nesol or deltasone or prednisone or cortan or liquid next pred
or meticorten or paramethasone or triamcinolone or aristocort or
volon or atolone or kenacort or orasone or panasol or prednicen)
.tw
30 24 or 28 or 29
31 23 and 30
Appendix 2. Data extraction form
REF ID: Study title:
Date of extraction: Extracted by:
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General comments/notes (internal for discussion):
Flow chart of trial
Group A (Intervention) Group B (Comparison)
No. of people screened
No. of participants randomised - all
No. randomised to each group
No. receiving treatment as allocated
No. not receiving treatment as allocated
- Reason 1
- Reason 2
No. dropped out
(no follow-up data for any outcome avail-
able)
No. excluded from analysis1 (for all out-
comes)
- Reason 1
- Reason 2
1This should be the people who received the treatment and were therefore not considered ’drop-outs’ but were excluded from all
analyses (e.g. because the data could not be interpreted or the outcome was not recorded for some reason)
Information to go into ’Characteristics of included studies’ table
Methods X arm, double/single/non-blinded, [multicentre] parallel-group/
cross-over/cluster-RCT, with x duration of treatment and x dura-
tion of follow-up
Participants Location: country, no of sites etc.
Setting of recruitment and treatment:
Sample size:
• Number randomised: x in intervention, y in comparison
• Number completed: x in intervention, y in comparison
Participant (baseline) characteristics:
• Age:
• Gender:
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(Continued)
• Main diagnosis: [as stated in paper]
• Polyps status: x % with polyps/no information [add info on
mean polyps score if available]
• Previous sinus surgery status: [x% with previous surgery]
• Previous courses of steroids: [add info on mean number of
courses if available]
• Other important effect modifiers, if applicable (e.g. aspirin
sensitivity, comorbidities of asthma):
Inclusion criteria: [state diagnostic criteria used for CRS, polyps
score if available]
Exclusion criteria:
Interventions Intervention (n = x): drug name, method of administration, dose
per day/frequency of administration, duration of treatment
Comparator group (n = y):
Use of additional interventions (common to both treatment arms)
:
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Health-related quality of life, disease-specific
• Disease severity symptom score
• Significant adverse effects: [review specific]
Secondary outcomes:
• Health-related quality of life, generic
• [Other review specific, pre-specified adverse events]
• [Other review specific, pre-specified adverse events]
• Endoscopy (polyps size or overall score)
• CT scan
Other outcomes reported by the study:
• [List outcomes reported but not of interest to the review]
Funding sources ’No information provided’/’None declared’/State source of fund-
ing
Declarations of interest ’No information provided’/’None declared’/State conflict
Notes
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Quote: “…”
Comment:
Allocation concealment (selection bias) Quote: “…”
Comment:
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(Continued)
Blinding of participants and personnel
(performance bias)
Quote: “…”
Comment:
Blinding of outcome assessment (detection
bias)
Quote: “…”
Comment:
Incomplete outcome data (attrition bias) Quote: “…”
Comment:
Selective reporting (reporting bias) Quote: “…”
Comment:
Other bias (see section 8.15)
Insensitive/non-validated instrument?
Quote: “…”
Comment:
Other bias (see section 8.15) Quote: “…”
Comment:
Findings of study: continuous outcomes
Results (continuous data table)
Outcome Group A Group B Other summary stats/Notes
Mean SD N Mean SD N Mean difference (95% CI), P values etc.
Disease-spe-
cific HRQL
(instrument
name/range)
Time point:
Generic
HRQL
(instrument
name/range)
Time point:
Symptom
score (overall)
(instrument
name/range)
Time point:
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(Continued)
Added total -
if scores re-
ported
separately for
each symptom
(range)
Time point:
Nasal
blockage/
obstruction/
congestion
(instrument
name/range)
Nasal
discharge
(instrument
name/range)
Facial pain/
pressure
(instrument
name/range)
Smell (reduc-
tion)
(instrument
name/range)
Headache
(instrument
name/range)
Cough (in
children)
(instrument
name/range)
Polyp size
(instrument
name/range)
CT score
(instrument
name/range)
Comments:
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Results (dichotomous data table)
Outcome Ap-
plicable review/
intervention
Group A Group B Other summary
stats/notes
No. of people
with events
No. of people
analysed
No. of people
with events
No. of people
analysed
P values, RR
(95% CI), OR
(95% CI)
Epistaxis/nose
bleed
INCS
Saline irrigation
Local irritation
(sore throat, oral
thrush, discom-
fort)
INCS
Saline irrigation
Os-
teoporosis (min-
imum 6months)
INCS
Stunted growth
(children, mini-
mum 6 months)
INCS Can also be mea-
sured as average
height
Mood
disturbances
OCS
Gastrointestinal
disturbances
(diarrhoea, nau-
sea, vom-
iting, stomach ir-
ritation)
OCS
Antibiotics
Insomnia OCS
Os-
teoporosis (min-
imum 6months)
INCS
OCS
Discomfort Saline irrigation
Suspected aller-
gic reaction (rash
or skin irritation
Antibiotics
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(Continued)
Anaphylaxis
or other serious
allergic reactions
such as Stevens-
Johnson
Antibiotics
Comments:
C O N T R I B U T I O N S O F A U T H O R S
Karen Head: reviewed and edited the protocol, screened abstracts and the full text of papers, extracted data from the included studies,
completed the data analysis and drafted the text of the review report.
Lee Yee Chong: scoped, designed and wrote the protocol, screened abstracts and the full text of papers, extracted data from the included
studies and helped to draft and review the text of the report.
Claire Hopkins: clinical guidance at all stages of project scoping and protocol development. Clinical input into data analysis, reviewing
and editing the report.
Carl Philpott: clinical guidance at all stages of project scoping and protocol development. Clinical input into data analysis, reviewing
and editing the report.
Martin J Burton: helped to draft the protocol; clinical guidance at all stages of project scoping and protocol development. Clinical
input into data analysis, reviewing and editing the report.
Anne GM Schilder: clinical input into data analysis, reviewing and editing the report.
D E C L A R A T I O N S O F I N T E R E S T
Lee Yee Chong: none known.
Karen Head: none known.
Claire Hopkins: I have received financial support from several companies involved in producing instruments for sinus surgery: Acclarent,
Sinusys, Cryolife and Medtronic.
Carl Philpott: I have previously received consultancy fees from the companies Acclarent, Navigant, Aerin Medical and Entellus.
Anne GM Schilder: Professor Anne Schilder is joint Co-ordinating Editor of the Cochrane ENTGroup, but had no role in the editorial
process for this review. Her evidENT team at UCL is supported by her NIHR Research Professorship award with the remit to develop
a UK infrastructure and programme of clinical research in ENT, Hearing and Balance. Her institution has received a grant from GSK
for a study on the microbiology of acute tympanostomy tube otorrhoea.
Martin J Burton: Professor Martin Burton is joint Co-ordinating Editor of the Cochrane ENT Group, but had no role in the editorial
process for this review.
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
Funding to complete a suite of reviews on medical interventions for chronic rhinosinusitis in 2015/2016 (award reference 14/174/
03), in addition to infrastructure funding for Cochrane ENT
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As part of the discussions about the use of a total symptom score we noted that many papers within the suite of reviews did not present
information for all four elements of the EPOS criteria for defining chronic rhinosinusitis (EPOS 2012). In particular, many studies
that only included patients with nasal polyps did not present information on facial pressure or pain. We made the decision that where
individual symptoms were recorded, they should be presented within the outcome of disease severity symptom score within the paper
as this information would be useful for the reader.
53Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
